A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models

por Zhang, Nannan, Zhang, Guo, Liu, Ning, Lin, Wanting, Ji, Sen, Zheng, Mingwu, Chen, Kai, Liang, Xiao, Li, Guobo, Ma, Yu, Zhu, Jun, Niu, Ting, Li, Lin-Li, Li, Jiong, Wei, Yu-Quan, Yang, Sheng-Yong
Publicado 2017